A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.

Also called NCT04308590

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 137 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04308590
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Bulgaria, Germany, Israel, Italy, Poland, Romania, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04308590. Randomized; triple masking; primary purpose treatment. Start 2020-07-27 (actual); primary completion 2024-09-19 (actual). Results posted on 2025-08-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Acronym
GRADIENT
Condition
Hypercortisolism
Intervention (Drug)
Relacorilant
Intervention (Other)
Placebo
Lead sponsor
Corcept Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct04308590
Content hash
c7ab0f2b19a1cfed82c19e52c0d0bbecc17fdd3a0f577db7f8b948eb6a5615a2